Ketamine (Ketaset)

Ketamine is a dissociative anesthetic agent that has been a cornerstone of equine anesthesia for decades, providing reliable induction of general anesthesia and serving as a component of both hospital and field anesthetic protocols. Marketed under brand names including Ketaset and Vetalar, ketamine is classified as a Schedule III controlled substance due to its potential for abuse, requiring appropriate documentation and security measures in veterinary practice. Despite the regulatory requirements, ketamine remains one of the most commonly used injectable anesthetics in equine medicine due to its established efficacy, predictable effects, and favorable safety profile when used appropriately.

The mechanism of action of ketamine involves antagonism of N-methyl-D-aspartate receptors in the central nervous system, producing a unique state of dissociative anesthesia characterized by profound analgesia, unconsciousness, and amnesia while preserving many protective reflexes and cardiovascular function. Unlike other general anesthetics that produce dose-dependent depression of vital functions, ketamine typically maintains or even enhances sympathetic tone, resulting in preservation of heart rate and blood pressure during induction. This cardiovascular stability makes ketamine particularly valuable for compromised patients who may not tolerate the cardiovascular depression associated with other agents.

Ketamine is supplied as an aqueous solution typically containing 100 milligrams per milliliter for equine use. Administration is most commonly intravenous for controlled induction, though intramuscular injection is possible for situations where intravenous access cannot be established. The drug is rarely used as a sole agent in horses due to the muscle rigidity it produces; instead, ketamine is combined with muscle relaxants such as guaifenesin or benzodiazepines and with alpha-2 adrenergic agonists that provide sedation and further muscle relaxation. These combination protocols have become standard approaches to equine anesthetic induction and total intravenous anesthesia.

The safety profile of ketamine in horses is well established through decades of clinical use. When combined with appropriate premedication and muscle relaxation, ketamine provides smooth, controllable induction with rapid transition to recumbency suitable for intubation or continuation with injectable or inhalant maintenance. Recovery from ketamine anesthesia depends significantly on dosing, duration, and concurrent medications, with properly managed cases typically showing acceptable recovery quality. As a controlled substance, ketamine requires secure storage, accurate record keeping, and appropriate prescribing practices.

The primary indication for ketamine in equine medicine is induction of general anesthesia prior to intubation and transition to inhalant maintenance or as part of total intravenous anesthesia protocols. Following appropriate premedication with alpha-2 adrenergic agonists and typically combined with a muscle relaxant, ketamine produces rapid loss of consciousness with sufficient depth for airway management and patient positioning. The relatively brief duration of a single induction dose allows for smooth transition to maintenance agents while the patient remains adequately anesthetized.

Field anesthesia represents a major application for ketamine in equine practice. The triple drip protocol combining guaifenesin, ketamine, and an alpha-2 agonist has been used for decades to provide balanced anesthesia outside hospital settings. Castrations, wound repairs, and other procedures performed at farms utilize ketamine as the hypnotic component of these combinations. The stability of ketamine in solution and the predictability of its effects make it well suited for field conditions where the precise control afforded by inhalant anesthesia is not available.

Short surgical procedures may be accomplished using ketamine-based protocols without transition to inhalant maintenance. Procedures expected to last fifteen to thirty minutes can often be completed with appropriate premedication, ketamine induction, and incremental redosing or constant rate infusion as needed. This approach simplifies anesthesia logistics for brief interventions while providing adequate surgical conditions. Longer procedures typically warrant transition to inhalant maintenance for better long-term control.

Emergency anesthesia situations may particularly benefit from ketamine's cardiovascular profile. Horses presenting for emergency surgery such as colic operations may have compromised cardiovascular status, and ketamine's maintenance of sympathetic tone can help preserve vital organ perfusion during induction. While careful management remains essential in compromised patients, ketamine offers advantages over some alternative induction agents in these challenging situations.

Subanesthetic doses of ketamine have been investigated for analgesic applications in horses, taking advantage of the drug's NMDA receptor antagonism without producing full dissociation. Chronic pain conditions and perioperative analgesia protocols have employed low-dose ketamine infusions to enhance pain control. While this application is less established than ketamine's anesthetic uses, ongoing research continues to explore optimal protocols for analgesic applications.

Ketamine dosing in horses requires veterinary expertise and must account for premedication, patient status, and the planned anesthetic protocol. The drug is administered intravenously for controlled induction in most circumstances, though intramuscular administration is possible when intravenous access is not available. All dosing decisions are made by the attending veterinarian based on comprehensive patient assessment, and the following represents general guidance rather than prescriptive recommendations.

Induction doses of ketamine in appropriately premedicated horses typically range from 2.0 to 2.5 milligrams per kilogram administered intravenously. Premedication with alpha-2 agonists such as detomidine, xylazine, or romifidine substantially improves induction quality by providing sedation, analgesia, and muscle relaxation that complement ketamine's effects. Without adequate premedication, ketamine produces unacceptable muscle rigidity that compromises induction quality and recovery. The specific premedication protocol influences the ketamine dose required, with heavily sedated patients often requiring less ketamine.

Combination with guaifenesin for induction involves concurrent administration of both drugs, typically with guaifenesin delivered by infusion while ketamine is given as a bolus when adequate muscle relaxation is observed. This approach allows titration of the muscle relaxant component to individual patient needs before committing to the irreversible step of ketamine administration. Alternative combinations using benzodiazepines such as diazepam or midazolam with ketamine are also employed, with the benzodiazepine typically administered immediately before or mixed with the ketamine.

Maintenance of anesthesia using ketamine involves either incremental boluses or constant rate infusion as part of total intravenous protocols. Triple drip solutions provide continuous delivery of ketamine along with guaifenesin and alpha-2 agonist, with infusion rates adjusted to maintain appropriate anesthetic depth. Typical maintenance delivery rates provide approximately two milligrams per kilogram per hour of ketamine, though substantial individual variation exists. Monitoring of anesthetic depth guides rate adjustments throughout the procedure.

Duration of ketamine effect following a single induction dose is relatively brief, typically ten to fifteen minutes of surgical anesthesia followed by progressive lightening. This characteristic makes ketamine suitable for short procedures as a sole maintenance agent but necessitates supplementation for longer operations. Cumulative dosing must be tracked throughout procedures, as excessive total ketamine can prolong recovery and affect recovery quality.

Intramuscular administration of ketamine is reserved for situations where intravenous access cannot be established. Higher doses are required due to less predictable absorption, and onset is slower and less controlled than intravenous administration. This route is generally less desirable for planned procedures but may be necessary for fractious patients or emergency situations. Recovery from intramuscular ketamine may be more prolonged and less predictable than following intravenous administration.

Ketamine produces characteristic effects that distinguish it from other anesthetic agents, including preservation or enhancement of cardiovascular function and maintenance of certain protective reflexes. Heart rate and blood pressure typically remain stable or increase during ketamine anesthesia, a feature that can be advantageous in compromised patients but requires monitoring to avoid excessive cardiovascular stimulation. The sympathomimetic effects result from central nervous system actions rather than direct cardiac effects.

Muscle rigidity represents a significant characteristic of ketamine anesthesia that necessitates combination with muscle relaxants for equine use. Without adequate muscle relaxation from concurrent medications, ketamine produces pronounced extensor rigidity that compromises induction quality, positioning, and recovery. This rigidity is not a side effect in the traditional sense but rather an inherent pharmacological property that must be managed through appropriate protocol design.

Respiratory effects of ketamine are generally less depressant than other anesthetic agents, with spontaneous ventilation often preserved during ketamine anesthesia. However, hypoventilation can occur, particularly when ketamine is combined with other respiratory depressants, and monitoring of respiratory function remains essential. Oxygen supplementation and preparation for ventilatory support should be available during any anesthetic event regardless of the specific agents employed.

Recovery from ketamine anesthesia may include ataxia, excitement, and agitation as the drug's effects dissipate. The quality of recovery depends significantly on total dose, procedure duration, concurrent medications, and individual patient factors. Ketamine recoveries have historically been described as rough compared to some other agents, though appropriate protocol design including adequate premedication and controlled total dosing generally produces acceptable recovery quality.

Salivation and increased respiratory secretions can occur with ketamine administration. While less pronounced in horses than in some other species, these effects may warrant attention in patients undergoing procedures involving the airway. The preservation of laryngeal reflexes during ketamine anesthesia provides some protection against aspiration but does not eliminate the need for appropriate airway management.

Rarely, adverse reactions including hypersensitivity responses may occur. Horses with known sensitivity to ketamine should receive alternative agents. Severe cardiovascular effects are uncommon but can occur in patients with underlying cardiac conditions, as the sympathomimetic effects may exacerbate certain arrhythmias or increase myocardial oxygen demand.

Ketamine is contraindicated in horses with known hypersensitivity to the drug. Previous adverse reactions to ketamine should be documented and alternative anesthetic protocols employed for future procedures. The clinical history should be reviewed before any anesthetic event to identify potential contraindications.

Patients with increased intracranial pressure may experience further elevation following ketamine administration due to the drug's effects on cerebral blood flow and metabolic rate. Head trauma cases and horses with known or suspected central nervous system lesions warrant careful consideration before ketamine use. While the clinical significance in horses has not been as extensively studied as in other species, caution is appropriate in neurologically compromised patients.

Severe hypertension or cardiac arrhythmias represent relative contraindications to ketamine given the drug's cardiovascular stimulant effects. Horses with significant heart disease, particularly conditions involving outflow obstruction or demand-supply mismatch, may experience adverse effects from ketamine-induced cardiovascular stimulation. Alternative induction agents with cardiovascular depressant rather than stimulant properties may be more appropriate for these patients.

Glaucoma or other conditions involving elevated intraocular pressure warrant consideration before ketamine use. The drug can increase intraocular pressure, potentially worsening pre-existing conditions. While glaucoma is uncommon in horses compared to some other species, ophthalmic history should be considered when planning anesthetic protocols.

Open globe injuries present specific concerns for ketamine use due to both increased intraocular pressure effects and the potential for patient movement during dissociative anesthesia. Procedures involving globe repair require careful consideration of anesthetic approach, and ketamine may not be the optimal choice for these cases.

Ketamine interacts beneficially with several drug classes that complement its properties and are routinely combined in equine anesthetic protocols. Alpha-2 adrenergic agonists including xylazine, detomidine, and romifidine are essential adjuncts that provide sedation, analgesia, and muscle relaxation while reducing ketamine dose requirements. The combination of alpha-2 agonists with ketamine represents a cornerstone of equine anesthesia practice, with the sedative effects of alpha-2 agonists counteracting ketamine's propensity to cause excitement while the muscle relaxant properties address ketamine-induced rigidity.

Guaifenesin combined with ketamine produces the classic induction combination that has been used in horses for decades. The centrally acting muscle relaxant effects of guaifenesin complement ketamine's hypnotic properties, producing smooth induction with controlled transition to recumbency. Triple drip formulations incorporating guaifenesin, ketamine, and alpha-2 agonists leverage the synergistic effects of all three drug classes for balanced total intravenous anesthesia.

Benzodiazepines such as diazepam and midazolam enhance muscle relaxation and reduce ketamine dose requirements when used in combination protocols. The ketamine-diazepam or ketamine-midazolam combination offers an alternative to guaifenesin-based approaches, with the benzodiazepine providing anxiolysis and muscle relaxation. These combinations are commonly employed for hospital-based induction before transition to inhalant maintenance.

Opioid analgesics provide additive central nervous system depression and enhanced analgesia when combined with ketamine. Butorphanol, morphine, and other opioids used in equine anesthesia complement ketamine's analgesic effects while contributing to overall anesthetic depth. The combination typically allows reduced doses of both ketamine and the opioid while improving analgesia.

Inhalant anesthetics including isoflurane and sevoflurane typically follow ketamine induction for longer procedures. The residual effects of ketamine reduce initial inhalant requirements during the transition period, and anesthetists must account for this interaction when establishing maintenance concentrations. As ketamine effects wane, inhalant requirements increase, requiring appropriate monitoring and adjustment.

Drugs that enhance sympathomimetic effects should be used cautiously with ketamine given its cardiovascular stimulant properties. Concurrent administration of catecholamines or other sympathomimetic agents may produce additive cardiovascular effects that require monitoring and management.

Ketamine administration requires comprehensive monitoring throughout the anesthetic event and into the recovery period. Essential monitoring parameters include heart rate and rhythm, blood pressure, respiratory rate and pattern, oxygen saturation, and end-tidal carbon dioxide when available. Assessment of anesthetic depth through physical examination findings complements instrumental monitoring. The cardiovascular stimulation typical of ketamine does not eliminate the need for monitoring, as excessive stimulation can be problematic in certain patients.

Controlled substance regulations apply to ketamine as a Schedule III drug. Secure storage in locked compartments with access limited to authorized personnel is required. Accurate record keeping documenting acquisition, use, and disposal must be maintained. Prescribing and dispensing practices must comply with federal and state regulations. Diversion prevention measures should be implemented in all facilities using ketamine.

Special populations require modified approaches to ketamine use. Neonatal foals may have different pharmacokinetics than adult horses. Geriatric patients with reduced organ function may show altered drug handling and recovery characteristics. Pregnant mares require consideration of potential fetal effects, as ketamine crosses the placenta. Patients with cardiovascular disease require careful assessment of the risk-benefit ratio given ketamine's stimulant effects.

Competition horses receiving ketamine must observe extended withdrawal periods due to the drug's controlled substance status and potential for detection. FEI, USEF, and racing commission regulations specifically address ketamine, typically prohibiting its presence at any detectable concentration. The long detection times for ketamine and its metabolites necessitate careful planning when anesthesia is required for competitive horses. Complete records of ketamine administration facilitate regulatory compliance.

Recovery from ketamine anesthesia requires appropriate facilities and protocols. The potential for excitement and ataxia during emergence necessitates padded recovery areas and trained personnel. Some institutions employ pharmacological interventions to improve recovery quality, while others rely on environmental modifications and assisted recovery techniques. The specific approach depends on institutional capabilities, patient factors, and the anesthetic protocol employed.

Occupational safety considerations apply to ketamine handling. While injection volumes make accidental self-injection rare, chronic exposure concerns exist for personnel repeatedly handling the drug. Needlestick injuries should be reported and monitored. Security measures protect against diversion while also ensuring appropriate handling practices.

Ketamine must be stored in compliance with Schedule III controlled substance requirements, which mandate secure, locked storage with access limited to authorized personnel. Most facilities use dedicated controlled substance cabinets or safes that meet regulatory specifications. Storage should be at controlled room temperature, typically between 15 and 30 degrees Celsius, protected from light. The original packaging provides appropriate light protection when containers are stored properly.

Controlled substance record keeping requirements apply to all ketamine transactions. Acquisition from licensed distributors must be documented with appropriate DEA forms. Usage logs must record each administration including date, patient identification, dose, and administering veterinarian. Disposal of expired or unused ketamine must follow approved procedures with appropriate witnessing and documentation. Regular inventory reconciliation helps ensure accurate accounting and early detection of any discrepancies.

Handling of ketamine requires attention to security and personal safety. The drug should be withdrawn from storage only when needed for immediate use, and unused portions should be promptly returned to secure storage or disposed of appropriately. Accidental exposure through needle sticks or skin contact should be reported to occupational health personnel. While single exposure incidents are unlikely to produce significant effects, reporting ensures appropriate monitoring and documentation.

Partially used vials present inventory management challenges due to controlled substance accounting requirements. Institutional policies should address whether partial vials may be retained for future use or must be disposed of after each case. If retention is permitted, appropriate labeling and documentation facilitate accurate accounting. Many facilities choose to discard partial vials with witnessed disposal to simplify inventory management despite the additional cost.

Expired ketamine requires disposal through approved controlled substance destruction procedures. This typically involves rendering the drug unusable through mixing with absorbent materials or other approved methods, witnessed by a second authorized individual, with appropriate documentation. Some jurisdictions permit return to distributors or disposal through authorized reverse distribution services. Accumulation of expired inventory should be avoided through appropriate purchasing practices.

Draft horses and other large breeds require proportionally larger doses of ketamine based on body weight, with attendant increases in drug volume and cost. The standard 100 milligram per milliliter concentration keeps volumes manageable even for larger patients, but horses exceeding 700 kilograms receive substantial drug quantities. Recovery management for draft horses requires facilities designed to accommodate their size and strength, as ketamine recoveries can include significant activity that poses injury risk.

Light horse breeds and warmbloods constitute the majority of horses receiving ketamine anesthesia and generally respond predictably to standard protocols. Individual variation in sensitivity exists, and titration to effect guides final dosing. Performance horses in these categories frequently require anesthesia for orthopedic procedures, and the controlled substance status of ketamine necessitates careful attention to competition withdrawal times that may substantially exceed pharmacological duration of action.

Ponies and miniature horses may require somewhat higher doses of ketamine per kilogram than full-sized horses based on their higher metabolic rates. Careful calculation based on accurate body weight is essential to avoid underdosing or overdosing in these smaller patients. The reduced physical size facilitates handling during induction and recovery phases, potentially reducing injury risk during these critical periods.

Quarter Horses and related breeds should be evaluated for malignant hyperthermia susceptibility when planning anesthesia. While ketamine is not considered a triggering agent for malignant hyperthermia in the same manner as halogenated inhalant anesthetics, comprehensive anesthetic planning for horses with known susceptibility or relevant genetic background should address all potential concerns. HYPP-positive horses require attention to potassium management throughout anesthesia, though ketamine does not directly affect potassium balance.

Horses with PSSM or other myopathies warrant careful consideration when planning ketamine anesthesia. The muscle rigidity characteristic of ketamine could theoretically exacerbate underlying muscle conditions, though clinical reports of specific problems are limited. Adequate muscle relaxation through concurrent medications and appropriate positioning with padding may be particularly important in horses with known muscle disorders.

Tiletamine combined with zolazepam, marketed as Telazol, represents an alternative dissociative combination used in some equine applications. This fixed-ratio combination provides both dissociative anesthesia and benzodiazepine muscle relaxation in a single product. While less commonly used than ketamine-based protocols in horses, tiletamine-zolazepam offers convenience for certain applications. The pharmacological profile differs somewhat from ketamine, and clinicians should be familiar with the specific characteristics of each option.

Propofol and alfaxalone offer non-dissociative alternatives for anesthetic induction in horses. These agents produce different cardiovascular effects than ketamine, with generally more pronounced depression that may be disadvantageous in compromised patients but preferable in horses with cardiac conditions where stimulation is undesirable. The choice between dissociative and non-dissociative induction agents depends on patient factors, available equipment, and clinician preference.

Guaifenesin serves as the essential muscle relaxant partner for ketamine in triple drip and similar protocols. Without adequate muscle relaxation, ketamine's utility in horses is limited by unacceptable rigidity. Understanding guaifenesin's properties and appropriate dosing is essential for clinicians using ketamine-based protocols.

Alpha-2 adrenergic agonists including xylazine, detomidine, romifidine, and medetomidine provide sedation and analgesia that complement ketamine anesthesia. These drugs are essential premedication for ketamine use in horses and contribute to triple drip formulations. Selection among available alpha-2 agonists depends on desired duration, cardiovascular effects, and specific protocol requirements.

Inhalant anesthetics provide the alternative approach to ketamine-based total intravenous protocols for extended procedures. Isoflurane and sevoflurane offer excellent control over anesthetic depth for lengthy surgeries, while ketamine protocols are generally reserved for shorter procedures or field conditions. Many horses receive ketamine induction followed by inhalant maintenance, combining the advantages of both approaches.